Sun Pharma Q1 net rises 31% to Rs 1,387 crore on lower R&D expenses

India's largest drugmaker has raised focus on specialty and limited competition products in the wake of pricing pressure in the US

Sun Pharmaceutical Industries has commenced pre-clinical research to develop new specialty drugs, the company announced after reporting a net profit of Rs 1,387 crore in the first quarter (April-June) of 2019-20.

This was 31 per cent higher on a year-on-year basis, on the back of revenue growth, lower research and development (R&D) expenses and foreign exchange gain. “We have recorded growth across most of the markets for the quarter and our performance is in line with our full-year guidance. We are consistently focusing to ensure reasonable returns for our generics business. At the same time, we continue our unwavering efforts